French drugmaker Sanofi pledged more cost cuts to increase margins as it relies ever more on its star eczema treatment to boost earnings, in the face of pressure to come up with a COVID-19 vaccine to tackle the global pandemic. The drugmaker said on Friday earnings per share would grow further this year after it posted stronger-than-expected fourth quarter results. Sanofi and Britain's GlaxoSmithKline stunned investors in December last year by warning a traditional, protein-based COVID-19 vaccine they are developing showed an insufficient immune response in older people, delaying its launch towards the end of 2021.